Abstract
This controlled feeding study investigated the influence of choline intake ranging from 300 to 2200mg/d on biomarkers of choline status. Mexican American men (n=60) differing in methylenetetrahydrofolate reductase (MTHFR) C677T genotype (29 677TT, 31 677CC) consumed a diet providing 300mg/d choline plus supplemental choline intakes of 0, 250, 800 or 1900 mg/d for total choline intakes of 300, 550 (choline AI), 1100 or 2200mg/d, respectively for 12‐wk; 400mcg/d as dietary folate equivalents and 173mg/d betaine were consumed throughout the study. Plasma choline and betaine increased (P<0.05) in response to 550, 1100 and 2200mg/d choline (2200>1100=550) whereas no change was observed on the 300mg/d group. Plasma phosphatidylcholine declined (P<0.05) in response to 300mg/d possibly due to declining folate status; no changes were observed in the other choline intake groups. After a methionine load, choline intakes of 1100 and 2200 mg/d groups attenuated (P<0.006) the rise in plasma tHcy relative to the 300 and 550 mg/d groups. No changes in plasma ALT or AST concentrations were detected regardless of choline intake. These data suggest that 550 mg/d choline is sufficient to prevent liver dysfunction in this population; higher intakes are needed to optimize other measured end‐points. Supported by NIH Grant #S06GM053933.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
